Antoreb Drug Interactions

Hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, ketoconazole, and erythromycin have all been found to have no clinically significant drug interactions in clinical pharmacokinetic investigations. Rifampicin and fluconazole have been shown to lower the active metabolite levels. The clinical consequences of these interactions have not been evaluated.
Concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt replacements containing potassium might cause an increase in serum potassium, just as other medications that block angiotensin II or its effects.
Lithium excretion may be lowered, just like other medicines that impact sodium excretion. If lithium salts are to be co-administered with angiotensin II receptor antagonists, serum lithium levels should be closely monitored.
Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) may reduce the effect of diuretics and other antihypertensive drugs. Therefore, the antihypertensive effect of angiotensin II receptor antagonists may be attenuated by NSAIDs including selective COX-2 inhibitors.
In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs including selective cyclooxygenase-2 inhibitors, the co-administration of angiotensin II receptor antagonists may result in a further deterioration of renal function. These effects are usually reversible.